The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without clotting factor inhibitors. Orphan drug designation is given to treatment candidates that have the potential to be safe and effective…

I love a good laugh. When things are terrible and the world seems to be imploding, a well-timed joke or story can completely change the direction of the day. I am grateful to live in a home that is filled with love and laughter. I can count on…

For some patients with moderate or severe hemophilia, switching from standard to extended half-life replacement therapy results in improvements in key outcome measures, a study in Canada found. Most of these self-reported gains in health-related quality of life, and physical, mental, and social functioning three months after the switch,…

Hemophilia patients experienced improvements in joint health, mobility, and overall quality of life after completing a supervised eight-week exercise program, a study reports. However, in order to achieve long-lasting benefits, regular exercise may be required. The study, “Effects of a supervised therapeutic exercise program on musculoskeletal health and…

I live with depression, anxiety, and chronic pain, and I rely on talk therapy at least once a month to keep my emotional well-being in check. The process of talking through my emotions and trusting a professional to give me new perspectives on the issues I deal with brings…

I recently took a photo of my husband, Jared, looking after our daughter, Cittie. They were both snuggled up on a foam mattress laid out in front of the television. It was a sweet photo, but their perfect smiles and adorable cuddles obscured a dark reality: At the time, Jared…

Implanting bioscaffolds — 3D biological scaffolds made up of collagen and other molecules — carrying transformed liver cells into rats successfully triggered the production of factor VIII (FVIII), the clotting protein missing in people with hemophilia A. According to researchers, these bioscaffolds may be a therapeutic alternative to FVIII…

“L’hitraot” is a word I learned while living in Israel. It is a gentle way to say goodbye, essentially meaning “see you later.” I am transitioning to a new job at a nonprofit organization, and this will be my last column here at Hemophilia News Today. It has been an…

The first documented case of a previously untreated hemophilia B patient developing inhibitors against the extended half-life therapy Alprolix was described in a report from Canada. The report also shows how combining routine administration of Alprolix with medications that suppress the immune system can be used to stop…

I sit waiting for my youngest son to complete an MRI of his right ankle. He has been overwhelmed with pain from constant breakthrough bleeding episodes. For a while, recombinant factor VIII was working to treat his hemophilia and we were euphoric, but we soon learned that internal…